Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Genesis Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$4,497,962

629 payments

Through program year 2025, Genesis Clinical Research LLC is reported as receiving $4,497,962 in research payments, across 629 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $375,959 19
2024 Research $1,105,765 78
2023 Research $1,495,679 143
2022 Research $893,755 99
2021 Research $356,014 49
2020 Research $128,315 60
2019 Research $142,476 181

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $2,923,913 159 payments
  2. AbbVie, Inc. $445,681 121 payments
  3. F. Hoffmann-La Roche AG $208,758 6 payments
  4. Horizon Therapeutics plc $188,022 5 payments
  5. Braintree Laboratories, Inc. $137,495 10 payments
  6. GlaxoSmithKline, LLC. $121,275 40 payments
  7. Akebia Therapeutics Inc $113,218 172 payments
  8. Gilead Sciences, Inc. $98,288 14 payments
  9. Dynavax Technologies Corporation $76,300 51 payments
  10. Sanofi US Services Inc. $40,131 11 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1 Openlabel Singledose Parallelgroup Study to Evaluate the Pharmacokinetics of Pf07081532 in Adult Participants With Type 2 Diabetes Mellitus With Varying Degrees of Renal Impairment Relative to Participants Without Renal Impairment $408,504 14 payments
  2. A Phase 1 Openlabel Singledose Parallel Cohort Study to Assess the Pharmacokinetics and Safety of Fosmanogepix PF 07842805 in Adult Participants With Varying Degrees of Hepatic Impairment $390,639 13 payments
  3. A Phase 1 Openlabel Singledose Parallelgroup Study to Evaluate the Plasma Pharmacokinetics and Safety of Lorlatinib in Participants With Moderate and Severe Hepatic Impairment Relative to Participants With Normal Hepatic Function $376,520 23 payments
  4. A Phase 1 Openlabel Singledose Parallel Group Study to Assess Pharmacokinetics Safety and Tolerability of Pf07817883 in Adult Participants With Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment $280,296 9 payments
  5. Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain $276,724 59 payments
  6. A Phase 1 Nonrandomized Openlabel Study to Assess the Pharmacokinetics Safety and Tolerability of Pf07817883 in Adult Participants With Renal Impairment and Healthy Adult Participants With Normal Renal Function $260,710 8 payments
  7. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $250,790 26 payments
  8. A Phase 1 Openlabel Singledose Parallel Group Study to Compare the Pharmacokinetics of Pf07923568 in Adult Participants With Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment $241,617 13 payments
  9. A Phase1 Open-Label Study to Assess the Effect of Renal Impairment in Subjects Treated With CT388 $222,658 10 payments
  10. A Phase 1 Openlabel Singledose Parallel Group Study to Compare the Pharmacokinetics of Pf07081532 in Adult Participants With Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment $192,289 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record